Lutetium-177 Dotatate Improves PFS in Advanced Midgut Carcinoid Tumors

Lutetium-177 Dotatate Improves PFS in Advanced Midgut Carcinoid Tumors
Lutetium-177 Dotatate Improves PFS in Advanced Midgut Carcinoid Tumors

In patients with advanced, progressive, somatostatin receptor-positive midgut neuroendocrine tumors, treatment with lutetium-177 (177Lu)–Dotatate significantly improved progression-free survival and overall response rate compared with high-dose octreotide long-acting repeatable (LAR), a study published in The New England Journal of Medicine has shown.1

Patients with advanced midgut neuroendocrine tumors who have experienced disease progression during first-line treatment with a somatostatin analogue have limited therapeutic options. 177Lu–Dotatate is a peptide receptor radionuclide therapy that demonstrated encouraging efficacy in a phase 2 trial. Therefore, researchers sought to evaluate the efficacy and safety of 177Lu–Dotatate in a phase 3 trial.

For the open-label NETTER-1 clinical trial (ClinicalTrials.gov Identifier: NCT01578239), investigators enrolled 229 patients with well-differentiated, metastatic midgut neuroendocrine tumors. Participants were randomly assigned 1:1 to 177Lu-Dotatate at a dose of 7.4 GBq every 8 weeks for 4 doses plus best supportive care, including intramuscular octreotide LAR given at a dose of 30 mg, or octreotide LAR alone at a dose of 60 mg every 4 weeks.

Researchers estimated that 65.2% (95% CI, 50.0-76.8) of patients in the 177Lu-Dotatate group would be progression-free at month 20 compared with 10.8% (95% CI, 3.5-23.0) in the octreotide LAR alone group.

Results further showed that a significantly higher proportion of patients who received radionuclide therapy achieved a response than those in the control arm (18% vs 3%; P <.001).

A planned interim analysis also demonstrated that treatment with 177Lu-Dotatate may be associated with an overall survival benefit; however, the planned final analysis is required for confirmation.

Fewer than 10% of patients in the 177Lu-Dotatate group experienced clinically significant myelosuppression. Grade 3 to 4 neutropenia, thrombocytopenia, and lymphopenia occurred in 1%, 2%, and 9%, respectively, of patients in the experimental arm vs no patients in the control arm. Investigators observed no evidence of renal toxicity during the study period.

Reference

1. Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376:125-135.

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs